Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-08-15
2011-12-27
Weddington, Kevin E (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S560000
Reexamination Certificate
active
08084500
ABSTRACT:
A method of treating and preventing dyslipidemia, cardiovascular disease, type 2 diabetes, obesity and other diseases associated with the Metabolic Syndrome and of increasing the expression of genes that promote lipid oxidation in an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid is administered orally or parenterally to the animal.
REFERENCES:
patent: 6451439 (2002-09-01), Okamato
patent: 6593514 (2003-07-01), Cahoon
patent: 7560442 (2009-07-01), Susilo
patent: 7687544 (2010-03-01), Bassaganya-Riera
patent: 7834058 (2010-11-01), Bassaganya-Riera
patent: 2002/0045232 (2002-04-01), Qiu
patent: 2003/0126640 (2003-07-01), Cahoon
patent: 1175901 (2002-01-01), None
patent: 2002-265985 (2002-09-01), None
patent: 2002-176913 (2003-06-01), None
Bassaganya-Riera, J., K. Reynolds, et al (2004)Gastroenterology127(3): 777-91. “Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease”.
Center for Disease Control (2004). National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
Chawla, A., W. A. Boisvert, et al. (2001)Mol Cell7: 161-71. “A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis”.
Chinetti, G., S. Lestavel, et al. (2001)Nature Medicine7: 53-8. “PPAR-Alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foram cells through stimulation of the ABCA1 pathway”.
Davidson, M. H., A. Armani, et al. (2007)Am J Cardiol99: 3C-18C, “Safety considerations with fibrate therapy”.
Ginsberg, H. N. (2003)Am J Cardiol91(7A): 29E-39E. “Treatment for patients with the metabolic syndrome”.
Guri, A. J., R. Hontecillas, et al. (2008)J Nutr Biochem19: 216-28. “Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into while adipose tissue”.
Hellemans K., K. Kerckhofs, et al. (2007)FEBS J274: 6094-105. “Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity”.
Hossain, M. A., M. Tsujita, et al. (2008)Cardiovasc Pharmacol51: 258-66. “Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes”.
Hontecillas, R., M J. Wannemeulher, et al (2002)J Nutr132: 2019-27. “Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid”.
Knowler, W. C., R. F. Hamman, et al. (2005)Diabetes54: 1150-6. “Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program”.
Remick, J., H. Weintraub, et al. (2008)Cardiol Rev16: 129-41. “Fibrate therapy: an update”.
Tsunoda, M., N. Kobayashi, et al. (2008)Am J Physiol Endocrinol Metab294: E833-40. “A novel PPAr {alpha} agonist ameliorates insulin resistance in dogs fed a high-fat diet”.
Walczak, R. & Tontonoz, P. (2002)J Lipid Res43: 177-86. “PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism”.
Wang, Y. X., C. H. Lee, et al. (2003)Cell113(2): 159-70. “Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity”.
Blasiole Daniel A.
DeWitt Ross & Stevens S.C.
Nutrition Therapeutics, Inc.
Sara, Esq. Charles S.
Weddington Kevin E
LandOfFree
Method of using catalpic acid to treat dyslipidemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using catalpic acid to treat dyslipidemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using catalpic acid to treat dyslipidemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299709